Bozkus and colleagues demonstrated that mutated-CALR can be seen as a shared neoantigen, potentially eliciting antigen-specific response from both CD4+ and CD8+ T cells against MPN transformed cells. Here, CALR is linked to myeloproliferative neoplasm.